Logo image of EXEL

EXELIXIS INC (EXEL) Stock Fundamental Analysis

NASDAQ:EXEL - Nasdaq - US30161Q1040 - Common Stock - Currency: USD

46.15  +1.85 (+4.18%)

After market: 46.24 +0.09 (+0.2%)

Fundamental Rating

8

We assign a fundamental rating of 8 out of 10 to EXEL. EXEL was compared to 555 industry peers in the Biotechnology industry. EXEL gets an excellent profitability rating and is at the same time showing great financial health properties. An interesting combination arises when we look at growth and value: EXEL is growing strongly while it also seems undervalued. This makes EXEL very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year EXEL was profitable.
In the past year EXEL had a positive cash flow from operations.
EXEL had positive earnings in each of the past 5 years.
Each year in the past 5 years EXEL had a positive operating cash flow.
EXEL Yearly Net Income VS EBIT VS OCF VS FCFEXEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

The Return On Assets of EXEL (22.68%) is better than 98.38% of its industry peers.
Looking at the Return On Equity, with a value of 30.20%, EXEL belongs to the top of the industry, outperforming 97.84% of the companies in the same industry.
The Return On Invested Capital of EXEL (26.25%) is better than 98.56% of its industry peers.
The Average Return On Invested Capital over the past 3 years for EXEL is below the industry average of 14.78%.
The 3 year average ROIC (10.78%) for EXEL is below the current ROIC(26.25%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 22.68%
ROE 30.2%
ROIC 26.25%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
EXEL Yearly ROA, ROE, ROICEXEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 150

1.3 Margins

The Profit Margin of EXEL (27.99%) is better than 96.58% of its industry peers.
In the last couple of years the Profit Margin of EXEL has declined.
EXEL has a better Operating Margin (35.43%) than 98.56% of its industry peers.
In the last couple of years the Operating Margin of EXEL has declined.
EXEL has a better Gross Margin (96.78%) than 96.58% of its industry peers.
In the last couple of years the Gross Margin of EXEL has remained more or less at the same level.
Industry RankSector Rank
OM 35.43%
PM (TTM) 27.99%
GM 96.78%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
EXEL Yearly Profit, Operating, Gross MarginsEXEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXEL is creating value.
Compared to 1 year ago, EXEL has less shares outstanding
The number of shares outstanding for EXEL has been reduced compared to 5 years ago.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EXEL Yearly Shares OutstandingEXEL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EXEL Yearly Total Debt VS Total AssetsEXEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 12.36 indicates that EXEL is not in any danger for bankruptcy at the moment.
EXEL has a better Altman-Z score (12.36) than 89.01% of its industry peers.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 12.36
ROIC/WACC2.94
WACC8.93%
EXEL Yearly LT Debt VS Equity VS FCFEXEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B

2.3 Liquidity

EXEL has a Current Ratio of 3.50. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
EXEL has a Current ratio of 3.50. This is in the lower half of the industry: EXEL underperforms 60.00% of its industry peers.
A Quick Ratio of 3.44 indicates that EXEL has no problem at all paying its short term obligations.
With a Quick ratio value of 3.44, EXEL perfoms like the industry average, outperforming 41.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.5
Quick Ratio 3.44
EXEL Yearly Current Assets VS Current LiabilitesEXEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

8

3. Growth

3.1 Past

EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 205.56%, which is quite impressive.
The Earnings Per Share has been growing by 12.65% on average over the past years. This is quite good.
The Revenue has grown by 24.50% in the past year. This is a very strong growth!
EXEL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.51% yearly.
EPS 1Y (TTM)205.56%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%175%
Revenue 1Y (TTM)24.5%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%30.62%

3.2 Future

Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 25.80% on average per year.
Based on estimates for the next years, EXEL will show a quite strong growth in Revenue. The Revenue will grow by 11.19% on average per year.
EPS Next Y23.6%
EPS Next 2Y19.76%
EPS Next 3Y22.02%
EPS Next 5Y25.8%
Revenue Next Year7.43%
Revenue Next 2Y9.22%
Revenue Next 3Y11.04%
Revenue Next 5Y11.19%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EXEL Yearly Revenue VS EstimatesEXEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
EXEL Yearly EPS VS EstimatesEXEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 20.98, which indicates a rather expensive current valuation of EXEL.
Compared to the rest of the industry, the Price/Earnings ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 95.14% of the companies listed in the same industry.
EXEL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.45.
With a Price/Forward Earnings ratio of 17.39, EXEL is valued on the expensive side.
Based on the Price/Forward Earnings ratio, EXEL is valued cheaper than 93.87% of the companies in the same industry.
EXEL is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 21.90, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 20.98
Fwd PE 17.39
EXEL Price Earnings VS Forward Price EarningsEXEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaper than 96.04% of the companies in the same industry.
94.95% of the companies in the same industry are more expensive than EXEL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 15.33
EV/EBITDA 12.08
EXEL Per share dataEXEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

EXEL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of EXEL may justify a higher PE ratio.
A more expensive valuation may be justified as EXEL's earnings are expected to grow with 22.02% in the coming years.
PEG (NY)0.89
PEG (5Y)1.66
EPS Next 2Y19.76%
EPS Next 3Y22.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EXEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXELIXIS INC

NASDAQ:EXEL (7/3/2025, 7:20:56 PM)

After market: 46.24 +0.09 (+0.2%)

46.15

+1.85 (+4.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners94.07%
Inst Owner Change2.99%
Ins Owners2.2%
Ins Owner Change18.04%
Market Cap12.59B
Analysts76.92
Price Target42.14 (-8.69%)
Short Float %7.64%
Short Ratio6.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.83%
Min EPS beat(2)10.66%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)55.5%
Min EPS beat(4)10.66%
Max EPS beat(4)148.98%
EPS beat(8)6
Avg EPS beat(8)22.76%
EPS beat(12)9
Avg EPS beat(12)18.75%
EPS beat(16)12
Avg EPS beat(16)61.89%
Revenue beat(2)1
Avg Revenue beat(2)3.96%
Min Revenue beat(2)-1.38%
Max Revenue beat(2)9.31%
Revenue beat(4)3
Avg Revenue beat(4)12.55%
Min Revenue beat(4)-1.38%
Max Revenue beat(4)34.34%
Revenue beat(8)4
Avg Revenue beat(8)4.97%
Revenue beat(12)6
Avg Revenue beat(12)3.28%
Revenue beat(16)8
Avg Revenue beat(16)4.82%
PT rev (1m)8.88%
PT rev (3m)11.09%
EPS NQ rev (1m)0.86%
EPS NQ rev (3m)16.02%
EPS NY rev (1m)0.93%
EPS NY rev (3m)9.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.3%
Revenue NY rev (1m)-0.92%
Revenue NY rev (3m)3.72%
Valuation
Industry RankSector Rank
PE 20.98
Fwd PE 17.39
P/S 5.47
P/FCF 15.33
P/OCF 14.94
P/B 5.91
P/tB 6.09
EV/EBITDA 12.08
EPS(TTM)2.2
EY4.77%
EPS(NY)2.65
Fwd EY5.75%
FCF(TTM)3.01
FCFY6.52%
OCF(TTM)3.09
OCFY6.69%
SpS8.43
BVpS7.81
TBVpS7.58
PEG (NY)0.89
PEG (5Y)1.66
Profitability
Industry RankSector Rank
ROA 22.68%
ROE 30.2%
ROCE 33.41%
ROIC 26.25%
ROICexc 45.49%
ROICexgc 47.65%
OM 35.43%
PM (TTM) 27.99%
GM 96.78%
FCFM 35.71%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexcg growth 3Y9.55%
ROICexcg growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score9
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 72.88%
Cap/Sales 0.94%
Interest Coverage 250
Cash Conversion 99.8%
Profit Quality 127.55%
Current Ratio 3.5
Quick Ratio 3.44
Altman-Z 12.36
F-Score9
WACC8.93%
ROIC/WACC2.94
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)205.56%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%175%
EPS Next Y23.6%
EPS Next 2Y19.76%
EPS Next 3Y22.02%
EPS Next 5Y25.8%
Revenue 1Y (TTM)24.5%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%30.62%
Revenue Next Year7.43%
Revenue Next 2Y9.22%
Revenue Next 3Y11.04%
Revenue Next 5Y11.19%
EBIT growth 1Y298.52%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year34.7%
EBIT Next 3Y31.16%
EBIT Next 5Y1.16%
FCF growth 1Y209.54%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y181.52%
OCF growth 3Y20.43%
OCF growth 5Y5.84%